US Executive Compensation Proxy SEC Filings — August 31, 2026

31-08-2026

FingerMotion, Inc. is seeking stockholder approval to issue shares in excess of the Exchange Cap (12,256,260 shares) under Nasdaq Rule 5635(d) in connection with two senior secured convertible notes issued in May and August 2026, and to increase authorized common shares from 200,000,000 to 500,000,000. The August 2026 note has a principal of $5,000,000 with an OID of $700,000, netting $4,300,000, of which only $1.3M is immediately available. The proposals are dilutive to existing shareholders and could negatively impact the trading price of the common stock.

• · The August Note matures on the first anniversary of the closing date (August 16, 2026).
• · The initial fixed conversion price of the August Note is $0.35 per share.
• · The Floor Price resets automatically every six months.
• · The Minimum Price for the May Note was $0.81 and for the August Note was $0.29.
• · The Warrant has a five-year term and is subject to a price adjustment if the Company issues securities below the exercise price.
• · The Company must file a resale registration statement within 15 calendar days of the August Registration Rights Agreement.
• · The Board may abandon the Certificate of Amendment at any time prior to effectiveness without further stockholder action.
• · The proposal requires a majority of shares present or represented by proxy at the Special Meeting; broker non-votes will not affect the outcome.

31-08-2026

NSTS Bancorp, Inc. is seeking stockholder approval for its acquisition by Brookfield Bancshares, Inc. in an all-cash merger valued at approximately $14.28 per share. The special meeting will be held on September 29, 2026, and the board unanimously recommends voting FOR the merger. However, shareholders should note that failing to vote has the same effect as an 'AGAINST' vote, so active participation is critical to the deal's completion.

• · Merger Agreement dated May 12, 2026.
• · Record date: August 14, 2026.
• · Total assets of NSTS Bancorp as of June 30, 2026: $269.9 million; total deposits $184.1 million; total stockholders' equity $80.1 million.
• · Parent (Brookfield Bancshares) had total assets of $420.2 million and total loans of $389.9 million as of June 30, 2026.
• · Voting agreements in place covering approximately 5.2% of total eligible votes (directors and executive officers).
• · Conditions include majority stockholder vote and regulatory approvals.

31-08-2026

Catheter Precision, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders, seeking the election of David A. Jenkins as a Class II director for a three-year term. The filing also details director compensation reductions, with cash fees cut from $50,000 to $30,000 effective July 1, 2024, and discloses that three of four directors are independent under NYSE American rules. The board held ten meetings in fiscal 2025, and all directors met at least 75% attendance requirements.

• · Stockholder proposals for 2027 Annual Meeting must be received between June 17, 2027 and July 17, 2027.
• · Audit committee comprises James Caruso (Chair) and Andrew Arno; compensation committee comprises Martin Colombatto (Chair) and James Caruso; nominating committee comprises Andrew Arno (Chair) and Martin Colombatto.
• · Director Jenkins previously founded companies sold for approximately $93 million (EP MedSystems) and $267 million (Transneuronix).
• · No family relationships exist among directors or executive officers.

31-08-2026

Envoy Medical, Inc. filed a definitive proxy statement (DEF 14A) for a special meeting of stockholders to be held on October 12, 2026. The primary proposal is to approve a reverse stock split of its Class A Common Stock at a ratio between 1-for-5 and 1-for-25, at the Board's discretion, before December 31, 2026. The filing also includes an adjournment proposal to ensure sufficient votes. The Board recommends a vote 'FOR' both proposals.

• · Record date for voting is August 19, 2026.
• · Special Meeting date is October 12, 2026 at 9:00 a.m. local time at 4875 White Bear Parkway, White Bear Lake, MN.
• · Reverse stock split ratio range is 1-for-5 to 1-for-25.
• · Approval requires affirmative vote of a majority of shares present and entitled to vote at the meeting.
• · Abstentions have the same effect as a vote 'Against' the proposals.
• · Broker non-votes will have no effect on the outcome.

31-08-2026

NEOS ETF Trust filed a definitive proxy statement (DEF 14A) on August 31, 2026, for a special meeting of shareholders scheduled for November 3, 2026. The meeting seeks shareholder approval of two proposals: (1) a new investment advisory agreement with NEOS Investment Management, LLC following the acquisition of NEOS Investments by GSAM Neptune Holdings, L.P., a subsidiary of The Goldman Sachs Group, Inc., and (2) the election of 14 new trustees to the Board, replacing all six current trustees. The transaction is expected to close in Q4 2026 or Q1 2027, and the new agreement maintains the same management fee, services, and portfolio managers, with no change to each fund's investment objective or share count.

• · The record date for voting is August 24, 2026.
• · The special meeting will be held on November 3, 2026, at 9:00 a.m. Eastern Time at NEOS's offices in Westport, CT.
• · The transaction agreement was dated August 10, 2026.
• · All 14 nominees currently serve on boards of other GSAM-managed funds.
• · The current Board has 6 members; all will be replaced if Proposal 2 passes.
• · The new agreement does not change the management fee paid by the funds.
• · Goldman intends to devote additional resources to NEOS and the Funds post-transaction.
• · Shareholders can vote by proxy card, telephone, or internet.
• · Alliance Advisors, LLC is acting as proxy solicitor and can be reached at (866) 206-8173.

31-08-2026

Spark I Acquisition Corp is seeking shareholder approval to extend its deadline to complete a business combination from September 29, 2026 to an extended date, primarily to allow time to close its proposed merger with ZincFive. The company has already missed its original July 11, 2025 deadline and has drawn down $1.9 million from a convertible note with the sponsor. While the board believes the ZincFive deal is compelling, the extension requires additional sponsor loans and shareholders may redeem shares at approximately $10.92 per share, with $84.8 million already redeemed in a prior extension.

• · The Company missed its original business combination deadline of July 11, 2025.
• · The First Extension extended the deadline to September 29, 2026.
• · The proposed Second Extension would extend the deadline further to the Extended Date.
• · The Merger Agreement with ZincFive was entered on June 11, 2026.
• · The Company has drawn the full $1.9 million under the Convertible Note as of the proxy date.
• · The Sponsor has agreed to make Second Extension Contributions of $0.015 per public share per month, up to $201,304.
• · The Extraordinary General Meeting is scheduled for September 25, 2026 at 10:00 a.m. ET.
• · Shareholders may redeem shares at a per-share price equal to the Trust Account balance divided by outstanding public shares.
• · The Board recommends voting FOR the Extension Proposal but expresses no opinion on redemption.

31-08-2026

Aptevo Therapeutics Inc. filed a definitive proxy statement (DEF 14A) for a special meeting of stockholders to be held on September 22, 2026. The board recommends voting FOR four proposals: (1) approval of an amended and restated certificate of incorporation, (2) approval of the issuance of shares and warrants representing 20% or more of outstanding common stock under Nasdaq rules, (3) approval of the Fifth Amended and Restated 2018 Stock Incentive Plan, and (4) authorization to adjourn the meeting if needed. As of the record date of August 13, 2026, there were 1,801,970 shares of common stock outstanding and entitled to vote.

• · The special meeting will be held virtually at www.virtualshareholdermeeting.com/APVO2026SM2 on September 22, 2026 at 10 a.m. Pacific Time.
• · The record date for voting is August 13, 2026.
• · Proposal 2 involves the issuance of shares and/or convertible securities equal to 20% or more of outstanding common stock or voting power, related to warrants issued under Inducement Letters and a Securities Purchase Agreement dated August 12, 2026.
• · Proposal 3 seeks approval of the Fifth Amended and Restated 2018 Stock Incentive Plan.
• · The proxy statement and proxy card were first mailed on or about August 31, 2026.

31-08-2026

GEE Group Inc. (JOB) filed a DEF 14A proxy statement for its 2026 Annual Meeting to be held virtually on September 24, 2026. The Board recommends shareholders vote FOR all six proposals, including the election of two Class I directors (Jyrl James and David Sandberg), ratification of Cherry Bekaert LLP as auditor, a 1-for-30 reverse stock split, an increase in authorized common shares from ~6.67 million (post-split) to 200 million, an advisory vote on executive compensation, and an adjournment proposal. As of the August 10, 2026 record date, there were 109,870,686 shares outstanding.

• · Annual Meeting will be held virtually on September 24, 2026 at 9:00 a.m. EDT.
• · Proxy materials first mailed or made available on or about September 4, 2026.
• · Record date for voting is August 10, 2026.
• · Proposal 3: 1-for-30 reverse stock split; Proposal 4: increase authorized shares from ~6.67M post-split to 200M.
• · Proposal 5 is a non-binding advisory vote on named executive officer compensation.
• · Brokers cannot vote on non-routine proposals (1, 3, 4, 5, 6) without instructions; Proposal 2 (auditor ratification) is routine.
• · Internet voting closes at 11:59 p.m. ET on September 23, 2026.